Investigators led by Sidney Kimmel Cancer Center—Jefferson Health (SKCC) and their collaborators from Memorial Sloan Kettering Cancer Center, University of California, San Francisco and Celgene Corporation have generated new findings that suggest targeting DNA-PK...